Evaluating texture-based prostate cancer classification on multi-parametric magnetic resonance imaging and prostate specific membrane antigen positron emission tomography
暂无分享,去创建一个
J. A. Gomez | R. Alfano | G. S. Bauman | J. Thiessen | I. Rachinsky | W. Pavlosky | J. Butler | M. Gaed | M. Moussa | J. L. Chin | S. Pautler | A. D. Ward | J. Chin | J. Thiessen | A. Ward | M. Gaed | M. Moussa | G. Bauman | S. Pautler | W. Pavlosky | I. Rachinsky | J. Butler | J. Gomez | R. Alfano
[1] Markus Schwaiger,et al. Current use of PSMA–PET in prostate cancer management , 2016, Nature Reviews Urology.
[2] Afaf R. Genady,et al. Automated synthesis of [18F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models , 2016, EJNMMI Research.
[3] Jin Tae Kwak,et al. Automated prostate cancer detection using T2-weighted and high-b-value diffusion-weighted magnetic resonance imaging. , 2015, Medical physics.
[4] Juan Hu,et al. Prostate cancer identification: quantitative analysis of T2-weighted MR images based on a back propagation artificial neural network model , 2015, Science China Life Sciences.
[5] Zixing Huang,et al. Comparison of PET/MRI with multiparametric MRI in diagnosis of primary prostate cancer: A meta-analysis. , 2019, European journal of radiology.
[6] Nico Karssemeijer,et al. Automated computer-aided detection of prostate cancer in MR images: from a whole-organ to a zone-based approach , 2012, Medical Imaging.
[7] Jan van der Meulen,et al. Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. , 2013, Radiology.
[8] A. Brickman,et al. Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. , 1995, The Journal of urology.
[9] A. Drzezga,et al. Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer , 2015, Molecular Imaging and Biology.
[10] M. Parmar,et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .
[11] Rhian Gabe,et al. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. , 2018, Health technology assessment.
[12] Thomas Hambrock,et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. , 2012, European urology.
[13] Aaron D. Ward,et al. Texture-based prostate cancer classification on MRI: how does inter-class size mismatch affect measured system performance? , 2019, Medical Imaging.
[14] Fuhui Long,et al. Feature selection based on mutual information criteria of max-dependency, max-relevance, and min-redundancy , 2003, IEEE Transactions on Pattern Analysis and Machine Intelligence.
[15] A. Fenster,et al. Toward Prostate Cancer Contouring Guidelines on Magnetic Resonance Imaging: Dominant Lesion Gross and Clinical Target Volume Coverage Via Accurate Histology Fusion. , 2016, International journal of radiation oncology, biology, physics.
[16] Jurgen J Fütterer,et al. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. , 2014, AJR. American journal of roentgenology.
[17] Carole Lartizien,et al. Computer-aided diagnosis of prostate cancer in the peripheral zone using multiparametric MRI , 2012, Physics in medicine and biology.
[18] J. Epstein,et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. , 2001, Human pathology.
[19] W. Oyen,et al. Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer , 2019, European urology.
[20] W. Catalona,et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. , 2004, The Journal of urology.
[21] P. Walsh,et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.